- ￥298 - 1313
- TargetMol
- USA
- T1492
- 2025年07月15日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20°C
- 保质期：
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -1532℃ for several months.
- 英文名：
Gemifioxacin mesylate
- 库存：
详询
- 供应商：
详询
- CAS号：
210353-53-0
- 规格：
5mg/25mg/100mg/1ml/10mM
| 规格： | 5mg | 产品价格： | ￥298.0 |
|---|---|---|---|
| 规格： | 25mg | 产品价格： | ￥717.0 |
| 规格： | 100mg | 产品价格： | ￥1313.0 |
| 规格： | 1ml/10mM | 产品价格： | ￥458.0 |
ID：T1492
PURITY：0.99
Formula：C19H24FN5O7S
MolWt：485.49
Appearance：白色粉末
Solubility：G4DMSO：30mg/mL
Bioactivity：Gemifloxacin is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Status：Factive, Oscient Pharmaceuticals
Pathways：DNA Damage/DNA Repair
Target：Topoisomerase inhibitor; DNA gyrase inhibitor
Receptor：Topoisomerase II ;DNA gyrase
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate
The major mechanism of imatinib resistance for patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine kinase that reduce the capacity of imatinib to inhibit kinase
-4 and C-5 centers ( 3 ). After formatron of the mesylate, from the recycled material the amine function is introduced through azrde displacement of the mesylate, followed by reduction ( 4 ) and protectron with the t -BOC group. Finally, the lactone
Inhibitors of Cellular Signaling Targets: Designs and Limitations
. Because of their central role in cellular signaling, as well as their primary role in disease progression, protein kinases are attractive therapeutic targets (2 ,3 ). Seven molecules targeting protein kinases, imatinib mesylate (Gleevec) and trastuzumab (Herceptin
技术资料暂无技术资料 索取技术资料
